Literature DB >> 21681456

[Anticholinergic agents for overactive bladder syndrome: current head-to-head comparison].

M Goepel1, D Schultz-Lampel.   

Abstract

Overactive-bladder syndrome is characterized by the symptoms pollakisuria, nocturia and urgency with and without urge incontinence. The primary diagnostic procedure includes noninvasive or minimally invasive techniques. Antimuscarinic drugs lead within the therapeutic cascade. Only after unsuccessful use of several antimuscarinics should further treatment options such as electromotive drug administration or infiltration of the detrusor muscle with botulinum toxin A be discussed. The presented review article tries to give an overview by including the existing head-to-head-studies in this field.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21681456     DOI: 10.1007/s00120-011-2602-y

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  15 in total

Review 1.  Botulinum toxin A in the overactive bladder: current status and future directions.

Authors:  Roger Dmochowski; Peter K Sand
Journal:  BJU Int       Date:  2007-02       Impact factor: 5.588

Review 2.  [How do medications used to treat urinary incontinence affect the cerebral function of the elderly?].

Authors:  M Goepel; K-C Steinwachs
Journal:  Urologe A       Date:  2007-04       Impact factor: 0.639

3.  Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg.

Authors:  Christopher R Chapple; Aino Fianu-Jonsson; Mark Indig; Vik Khullar; José Rosa; Roberto M Scarpa; Arun Mistry; D Mark Wright; John Bolodeoku
Journal:  Eur Urol       Date:  2007-06-06       Impact factor: 20.096

Review 4.  Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin.

Authors:  G G Kay; U Ebinger
Journal:  Int J Clin Pract       Date:  2008-08-11       Impact factor: 2.503

5.  Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity?

Authors:  Maurizio Serati; Stefano Salvatore; Stefano Uccella; Linda Cardozo; Pierfrancesco Bolis
Journal:  Eur Urol       Date:  2008-06-20       Impact factor: 20.096

6.  Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.

Authors:  Ling-Hong Tseng; Alex C Wang; Yao-Lung Chang; Yung-Kuei Soong; L Keith Lloyd; Yet-Jane Ko
Journal:  Neurourol Urodyn       Date:  2009       Impact factor: 2.696

Review 7.  The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis.

Authors:  Christopher R Chapple; Vik Khullar; Zahava Gabriel; Dominic Muston; Caty Ebel Bitoun; David Weinstein
Journal:  Eur Urol       Date:  2008-06-20       Impact factor: 20.096

8.  Prospective randomized comparison of oxybutynin, functional electrostimulation, and pelvic floor training for treatment of detrusor overactivity in women.

Authors:  Raquel M Arruda; Rodrigo A Castro; Gabriela C Sousa; Marair G F Sartori; Edmund C Baracat; Manoel J B C Girão
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-03-11

9.  Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants > or = 50 years.

Authors:  Brian Olshansky; Ursula Ebinger; José Brum; Mathias Egermark; Andrea Viegas; Ludmyla Rekeda
Journal:  J Cardiovasc Pharmacol Ther       Date:  2008-10-01       Impact factor: 2.457

10.  Comparison of fesoterodine and tolterodine in patients with overactive bladder.

Authors:  Christopher R Chapple; Philip E Van Kerrebroeck; Klaus-Peter Jünemann; Joseph T Wang; Marina Brodsky
Journal:  BJU Int       Date:  2008-07-21       Impact factor: 5.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.